Evaluation of technology export agreement based on market size and growth potential
[by Ji, Yong Jun] Abion disclosed on April 1 that it entered into a term sheet agreement (MOU) outlining the terms for the technology transfer of ‘vabametkib,’ an anticancer drug candidate (development code: ‘ABN401’), to a multinational pharmaceutical company headquartered in Russia and four member states of the Commonwealth of Independent States (CIS).
The pharmaceutical 온라인 바카라 사이트 involved in the agreement is a multinational corporation with multiple subsidiaries in San Diego, USA, and an extensive sales and distribution network across Russia and the CIS. While the specific financial terms of the contract were not disclosed due to confidentiality agreements, the 온라인 바카라 사이트 stated that discussions were held regarding a technology export contract, taking into account the market size and growth potential.
This collaboration is expected to facilitate the acquisition of clinical data on Caucasian patients, which will serve as an important foundation for future expansion into the U.S. and European markets. Additionally, the company aims to demonstrate the drug’s broad therapeutic potential by securing a term sheet agreement that encompasses not only vabametkib monotherapy but also combination therapy with lazertinib and its application in multiple indications, including hepatocellular carcinoma (HCC), gastric cancer, and glioblastoma (GBM). 온라인 바카라 사이트 emphasized that this initiative represents a phased strategy for future global market expansion and aligns with the company’s long-term growth objectives.
“This term sheet agreement represents a strategic approach to expanding global partnerships,” an 온라인 바카라 사이트 official said. “We will continue to pursue major global deals for our pipeline, including vabametkib.”
온라인 바카라 사이트 is currently in discussions for global partnerships with leading pharmaceutical companies in the United States and Europe. While the company initially focused on technology exports targeting key markets in North America and Europe, it received a proposal from a Russian pharmaceutical company and promptly entered into agreements covering Russia and four CIS countries.
온라인 바카라 사이트’s key pipeline candidate, vabametkib, is a non-small cell lung cancer treatment candidate that targets the hepatocyte growth factor receptor (c-MET) mutation. In addition to ongoing monotherapy clinical trials, the company is currently conducting a Phase 2 clinical trial evaluating vabametkib in combination with Yuhan Corporation's lazertinib.
On the other hand, 온라인 바카라 사이트 is scheduled to present preclinical findings on the efficacy of the combination therapy of lazertinib at the American Association for Cancer Research (AACR) Annual Meeting 2025, held in Illinois, USA, from April 25 to 30 (local time).